Dutch Kidney Foundation

Application form

Consortium Grant

*23 April 2020*

The Dutch Kidney Foundation (DKF) General Grant Requirements (Subsidievoorwaarden Nierstichting Nederland) apply to all awarded DKF subsidies as well as all proposals for DKF subsidies. Applicability of general and other conditions of the applicant, the applicant's institute and of third parties is explicitly excluded.

***Disclaimer***

*The execution of a DKF Call for proposals, selection of pre-proposals for full application and positive DKF grant award decisions are conditional on DKF revenues and budgetary means. The DKF explicitly reserves the right to cancel an initiated Call for proposals, to suspend a running procedure or to lower a grant amount in relation to earlier statements.*

Nierstichting / Dutch Kidney Foundation

+31 (0)35 697 8015

research@nierstichting.nl

**Instructions for completing and submitting this form**

The submitted proposal must meet the following conditions for acceptance in this call:

* Maximum word counts specified are fixed limits that must not be exceeded. Please fill in the number of words used where asked.
* Images (figures, tables, etc.) can be added in the text of Section II (Description) and Section IV (Organisation) and must each have a readable format and size. All images taken together must not exceed 4 pages and legends will count towards the maximum word count of Section II subsection 1 (Abstract) or Section IV subsection 1 (Consortium Collaboration and Synergy). No images are allowed in other sections.
* References are only allowed in sections that specifically ask for references.
* Please note that section VII (Patient Perspective) should be completed in Dutch.
* Forms should be filled in using Arial 10 pt.
* Instructions and/or sections in the form must not be deleted (even if the section is not applicable).
* Please convert the completed application form, including electronic signatures, in a searchable PDF file. Upload the PDF file into your digital submission form in our grant management system called MIDAS via [this link](https://midas.nierstichting.nl/aims/portal/scheme-call-description?call_id=201&call_id:sig=142+0+4C24E2328B2CA035CFBF7F4641D2A7C543F6C85E&applicant_type=individual&category_id=10009&category_id:sig=153+0+CD2EFDBB9D932719A2AC89139C740F095C2FA6F8). The maximum file size is 5 MB. Attachments are not accepted unless falling under item III.5 (Supporting Organisations).

**Project title:**

**Acronym (optional):**

**Applicant**

|  |  |
| --- | --- |
| Name (M/F) |  |
| Institute, DepartmentRoom numberPO boxPostal code, Town/City  |  |
| Phone |  |
| Email |  |
| Researcher Identification (e.g. ResearcherID, ORCID)  |  |

**Project**

|  |  |
| --- | --- |
| Expected start date |  |
| Expected end date |  |
| Duration in months  |  |
| Proposed DKF budget |  |

**Sections**

1. General Information
2. Research Description
3. Details Work Packages
4. Research Environment
5. Organisation
6. Products and Development
7. Impact and Valorization
8. Patiëntenperspectief
9. Funding
10. Signatures

I. GENERAL INFORMATION

**1. Participating Institutes**

*Specify the participating institutes.*

**Institute 1**

|  |  |
| --- | --- |
| Institute, DepartmentPO boxPostal code, Town/City |  |

**Institute 2**

|  |  |
| --- | --- |
| Institute, DepartmentPO boxPostal code, Town/City |  |

**Institute X**

|  |  |
| --- | --- |
| Institute, DepartmentPO boxPostal code, Town/City |  |

**2. Research Teams**

*Specify all participating teams, research departments and investigators.*

**Research team 1**

|  |  |
| --- | --- |
| Name Team Leader (M/F) |  |
| Institute, Department |  |
| Phone |  |
| Email |  |
| Researcher Identification (e.g. ResearcherID, ORCID)  |  |

**Investigators**

*Please provide the names of all funded and non-funded investigators in the project*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Name and title | Function | Institute and department | Funding source | Fte | Email address |
|  |  |  |  |  |  |

**Research team 2**

|  |  |
| --- | --- |
| Name Team Leader (M/F) |  |
| Institute, Department |  |
| Phone |  |
| Email |  |
| Researcher Identification (e.g. ResearcherID, ORCID)  |  |

**Investigators**

*Please provide the names of all funded and non-funded investigators in the project*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Name and title | Function | Institute and department | Funding source | Fte | Email address |
|  |  |  |  |  |  |

**Research team X**

|  |  |
| --- | --- |
| Name Team Leader (M/F) |  |
| Institute, Department |  |
| Phone |  |
| Email |  |
| Researcher Identification (e.g. ResearcherID, ORCID)  |  |

**Investigators**

*Please provide the names of all funded and non-funded investigators in the project*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Name and title | Function | Institute and department | Funding source | Fte | Email address |
|  |  |  |  |  |  |

II. RESEARCH DESCRIPTION

**1. Abstract (max. 1250 words)**

***Number of words used:***

*Please address the points below. A general subject review can be provided in item 3 and detailed descriptions of the work packages in item 6. All references must be put in item 4 and risk factors should be addressed in item 10.*

* *Central problem that will be addressed.*
* *Rationale of the project plan for solving the problem.*
* *Central hypothesis and aims.*
* *Concise description of the work packages and the interconnections.*
* *Expected deliverables of the overall project.*

*Note: The text provided in this item should be copied and pasted into the digital submission form in MIDAS.*

**2. General Subject Review (max. 750 words)**

***Number of words used:***

*Describe the current knowledge regarding the central problem that is addressed in the project plan. Provide a sound substantiation of the project rationale and the proposed solution to the problem.*

**3. Key References (max. 20 references)**

* *Provide the most important references here.*
* *Provide only references in this item or in item 6.*
* *Do not add references to the other items in this section.*

**4. Work Packages Overview (max. 400 words)**

***Number of words used:***

*Give concise descriptions of the Work Packages and their interconnections. A Work Package is defined as a conceptually relatively independent part of the consortium project. The total number of Work Packages may vary.*

**5. Time Schedule and Deliverables**

*Specify the timing of the work packages and research objectives and deliverables in a Gantt chart. Detailed descriptions of objectives and deliverables can be provided on the Work Package forms.*

**6. Human Studies (if applicable, max. 250 words)**

***Number of words used:***

*Please address all of the following points (or motivate if not relevant).*

* *Target group. Numbers of participants (patients and controls) required and numbers of subjects to be approached.*
* *Power calculation.*
* *Efforts required from participants (patients and controls) and possible risks of study participation.*
* *Inclusion strategy. Inclusion problems are common in clinical studies and have special attention of the DKF. What are possible obstacles for inclusion and which safeguards are taken? What are possible solutions if problems arise?*
* *Procedures (e.g. randomisation, blinding).*
* *Describe the arrangements with organisations and persons (not funded by this project) whose cooperation is necessary for successful inclusion and execution of the study.*
* *Time line for the “METC” (Ethical Review Committee) procedure.*

**7. Animal Studies (if applicable, max. 250 words)**

***Number of words used:***

* *Motivate the approach using animal studies to address the project’s problem rather than other research methods (e.g. in vitro studies using cells or cell lines, organoids, computer simulation).*
* *Choice of models. Motivate the models that are available and relevant for the project.*
* *Describe why and how the proposed models are representative for human physiology and disease.*
* *Procedures (e.g. randomisation, blinding).*
* *Motivate the numbers of animals required. Provide a power calculation.*
* *Time line for the "DEC" (Animal Research Ethical Committee) procedure.*

**8. Risk Factors (max. 500 words)**

***Number of words used:***

*Possible risk factors that limit the feasibility of the overall project. Please refer to the obstacles described for the work packages. Provide alternatives to overcome obstacles (plan B). Indicate how the risks will be addressed.*

III. DETAILS WORK PACKAGES

**Description of the Work Packages**

*Please complete the following section for each work package.*

**1. Work Package 1**

**1.1 Overview work package 2**

|  |  |
| --- | --- |
| Title |  |
| Work Package Leader |  |
| Research team(s) involved |  |
| Personnel involved | Name and title | Position | Institute & Department |
|  |  |  |

**1.2 Scientific description work package (max. 1500 words)**

***Number of words used:***

*Please address the following points.*

* *Aim(s), objectives and approach*
* *Rationale behind the approach*
* *Work plan*
* *Deliverables*
* *Risk factors*
	1. **Key References work package 1 (max. 10)**

**2. Work Package 2**

**2.1 Overview work package 2**

|  |  |
| --- | --- |
| Title |  |
| Work Package Leader |  |
| Research team(s) involved |  |
| Personnel involved | Name and title | Position | Institute & Department |
|  |  |  |

**2.2 Scientific description work package 2 (max. 1500 words)**

***Number of words used:***

*Please address the following points.*

* *Aim(s), objectives and approach*
* *Rationale behind the approach*
* *Work plan*
* *Deliverables*
* *Risk factors*

**2.3 Key References work package 2 (max. 10)**

**3. Work Package X**

**3.1 Overview work package X**

|  |  |
| --- | --- |
| Title |  |
| Work Package Leader |  |
| Research team(s) involved |  |
| Personnel involved | Name and title | Position | Institute & Department |
|  |  |  |

**3.2 Scientific description work package X (max. 1500 words)**

***Number of words used:***

*Please address the following points.*

* *Aim(s), objectives and approach*
* *Rationale behind the approach*
* *Work plan*
* *Deliverables*
* *Risk factors*

**3.3 Key References work package X (max. 10)**

IV. RESEARCH ENVIRONMENT

**1. Past Performance and Key Publications**

*Give a concise overview of past scientific performance of the research teams.*

**1.1a. Research Team 1 (max. 500 words)**

***Number of words used:***

**1.1b. References Team 1 (max. 10)**

**1.2a. Research Team 2 (max. 500 words)**

***Number of words used:***

**1.2b. References Team 2 (max. 10)**

**1.3. Research Team X (max. 500 words)**

***Number of words used:***

**1.3b. References Team X (max. 10)**

**2. Most important Previous Grants Awarded to the Research Teams (in the past 5 years)**

**2.1. Research Team 1**

**2.2. Research Team 2**

**2.3. Research Team X**

**3. Relation with other Relevant Research Projects and Previously Awarded DKF Grants (max. 250 words)**

***Number of words used:***

*If applicable, show how the present proposal is related to other projects and DKF grants. Show clearly that there is no overlap between projects.*

**4. Concise Principal Investigator CV (max. 500 words)**

***Number of words used:***

**5. Supporting Organisations (max. 100 words)**

***Number of words used:***

*If applicable, list the organisations (not participating in the project) that will provide essential support to perform this project, e.g. providing research products or knowledge, or contributing to the inclusion of patients. Attach letters of intent in separate pdf’s.*

**6. Patient participation (max. 200 words)**

***Number of words used:***

*Describe how patient participation is organized at the level of:*

* *Setup and design of the research proposal*
* *Monitoring and advice during execution of the studies*
* *Participation in the study (in case of patient studies**)*

V. ORGANISATION

**1.** **Consortium Collaboration and Synergy (max. 400 words)**

***Number of words used:***

*Give a description of the organisation of the consortium. Specify roles and expertise of the participating research teams. Demonstrate the interconnections and synergy of the consortium. Use charts (e.g. organisational charts, flow charts) to show the links between participating teams, Work Packages and proposed research.*

**2. External Collaboration and Advisers (max. 400 words)**

***Number of words used:***

*If applicable, specify the institutes and investigators who will be collaborating with the project (not funded by the project) and the external advisers to the project.*

**3. Management Plan (max. 400 words)**

***Number of words used:***

*Describe the decision structure, internal monitoring and communication, and the consortium meeting scheme.*

VI. PRODUCTS AND DEVELOPMENT

**1. Data Stewardship (max. 250 words)**

***Number of words used:***

*Describe the strategy for data management. Address the application of FAIR Data Principles (see* [*https://www.dtls.nl/fair-data/fair-principles-explained/*](https://www.dtls.nl/fair-data/fair-principles-explained/)*). Note that an awarded Consortium will have to supply a Data Sharing Plan.*

**2. Expected Research Data (max. 400 words)**

***Number of words used:***

* *Data types, quantities and formats*
* *Data quality and standards*
* *Privacy protection of participants*
* *Long-term preservation of data*

**3.** **Expected Research and Healthcare Products (max. 200 words)**

***Number of words used:***

*Describe the products expected to result from the project. Research products: e.g. animal models, assays, biological products, software, research protocols and procedures, laboratory technology. Healthcare products: e.g. medication, devices, software, guidelines, treatment protocols and healthcare procedures.*

**4. Intellectual Property Strategy (max. 200 words)**

***Number of words used:***

*Describe your strategy for deciding on protecting knowledge, skills, technology coming forth from this project (e.g. by way of patents, trade secrets, copyrights, trademarks, registered designs).*

**5. Development Strategy (max. 300 words)**

***Number of words used:***

*It is essential that developed knowledge, skills and technology are brought further into development towards the patient and the public. Therefore the necessary steps following the project have to be considered in an early stage.*

* *Describe which steps are needed after finishing the project to realize implementation.*
* *Describe which risks and opportunities you may face in the development steps and which anticipating actions you will take to make sure your project is optimally aligned to reach implementation.*

VII. IMPACT AND VALORISATION

**1. Strategy (max. 300 words)**

***Number of words used:***

* *How does the project fit in with “[Nierziekte de baas](https://www.nierstichting.nl/media/filer_public/14/ef/14ef1c2a-73f9-40f6-b833-afbc940dbd41/onderzoeksagenda_nierziekte_de_baas_-_gezamenlijke_agenda_oi_2017.pdf)”, the joint Dutch renal strategic agenda for innovation and research? (In English "*[*Beating kidney disease*](https://www.nierstichting.nl/media/filer_public/4d/6d/4d6d6b4e-ce56-4a4b-8ba2-f5ac957d0df8/beating_kidney_disease_-_joint_agenda_for_ri_june_2018.pdf)*".)*
* *How does the project fit in with the "[Nationale Wetenschaps Agenda](https://wetenschapsagenda.nl/publicatie/nationale-wetenschapsagenda-nederlands/)"?*

**2. Opportunities for Impact and Valorisation (max. 800 words)**

***Number of words used:***

*Describe and explain the possible impact of the project in the following fields:*

* *Kidney patients, future kidney patients and prevention of kidney disease. Include the communication and dissemination of results to patients.*
* *Renal science, technology and the renal field (scientific and clinical) in the Netherlands and abroad. Include the dissemination of results to the scientific community.*
* *Socio-economic aspects and health care innovation. Include the implementation and application of the products of the project (section V).*
* *Public awareness* *for kidney health and communication to the general public.*

VIII. Patiëntenperspectief

*Deze sectie van het aanvraagformulier is bedoeld voor de beoordeling vanuit het patiëntenperspectief door patiëntbeoordelaars van de Nierpatiënten Vereniging Nederland. Deze sectie moet de patiëntbeoordelaars helder inzicht geven in de aanvraag. De tekst moet begrijpelijk zijn voor mensen die niet werkzaam zijn in de wetenschap. Vermijd daarom het gebruik van vaktermen of zorg voor een duidelijke uitleg van het begrip. Deze sectie graag invullen in het Nederlands. Nota bene, de term patiënten kan ook betrekking hebben op donoren of naasten. Een vertegenwoordiger van de groep patiëntbeoordelaars zal aanwezig zijn bij de vergadering van de Wetenschappelijke Raad om het patiëntoordeel toe te lichten.*

**1. Doel en projectbeschrijving (max. 1750 woorden)**

***Aantal gebruikte woorden:***

*Geef een samenvatting van het voorgestelde project met een probleembeschrijving, de hypothese, het doel en het werkplan.*

**2. Relevantie (belang) van het onderzoek voor (toekomstige) patiënten (max. 300 woorden)**

***Aantal gebruikte woorden:***

*a. Beschrijf op welke manier het onderzoek:*

* *Aansluit bij behoeften van huidige en toekomstige patiënten*
* *Direct of indirect bijdraagt aan de verbetering van gezondheid*
* *Direct of indirect bijdraagt aan kwaliteit van leven, zelfredzaamheid en maatschappelijke participatie*
* *Direct of indirect bijdraagt aan de zorg in het algemeen*

*b. Benoem de uitkomstmaten op patiëntniveau (bijv. gezondheid, kwaliteit van leven, zelfstandigheid). Denk aan Patient Reported Outcome Measures (PROMs).*

**3. Haalbaarheid en risico’s (max. 200 woorden per studie)**

***Aantal gebruikte woorden:***

*Beschrijf de volgende punten:*

* *In- en exclusiecriteria*
* *Belasting voor de deelnemers (bijv. ondergaan van de behandeling/diagnostiek, invullen van vragenlijsten, duur van het onderzoek) ten opzichte van de standaard behandeling.* *Voeg bij voorkeur een flowchart of een tabel toe waarin alle tijdspunten en handelingen staan weergegeven*
* *Risico’s van deelname aan het onderzoek voor de deelnemers*

**4. Patiëntenparticipatie** (anders dan deelnemen aan de studie) **(max. 300 woorden)**

***Aantal gebruikte woorden:***

*Benoem de betrokkenheid van patiënten (ervaringsdeskundigen) bij het onderzoek. Geef aan in welke fasen de betrokkenheid terug te zien is (bijv. opzet van het projectplan, uitvoering van het onderzoek), en hoe deze wordt gefaciliteerd. Geef details over de ervaringsdeskundigen (bijv. aantal, kenmerken) en hun rol.*

*Meer informatie: 1)* [*‘De rol van patiënten in onderzoek’*](https://www.nvn.nl/media/1139/de-rol-van-patienten-in-onderzoek_wetenschappelijk.pdf) *(NVN); 2) ‘*[*Een 10 voor patiëntenparticipatie’*](https://www.zonmw.nl/uploads/tx_vipublicaties/Een_10_voor_patientenparticipatie.pdf) *(ZonMw); 3)* [*‘Kickstarter voor onderzoekers’*](https://participatiekompas.nl/kickstart-voor-onderzoekers) *(PGOsupport); 4) secretariaat@nvn.nl of 035-6912128*

**5. Resultaat en evaluatie patiëntenparticipatie (indien van toepassing, max. 300 woorden)**

***Aantal gebruikte woorden:***

*Beschrijf kort wat het betrekken van ervaringsdeskundigen bij dit projectplan heeft opgeleverd. Benoem en motiveer daarnaast welke suggesties van ervaringsdeskundigen niet verwerkt zijn in het projectplan.*

**6. Communicatie en begeleiding (max. 300 woorden)**

***Aantal gebruikte woorden:***

*a. Geef aan op welke manier deelnemers informatie ontvangen over deelname aan het onderzoek en op welke wijze de begeleiding van deelnemers tijdens het onderzoek geregeld is.*

*b. Beschrijf op welke manier er terugkoppeling plaatsvindt van resultaten naar de individuele deelnemers.*

*c. Beschrijf op welke manier de resultaten met (toekomstige) patiënten en het algemene publiek gedeeld zullen worden. Indien gewenst, raadpleeg de Nierstichting (research@nierstichting.nl) of de Nierpatiënten Vereniging Nederland (secretariaat@nvn.nl) voor suggesties rondom de communicatie van resultaten.*

VIII. FUNDING

**1. Budget Tables**

*Specify the proposed standard personnel years according to the DKF Project Funding Model (PFM). Consortium Grant proposals may include a budget for extra expenses (outside the PFM lump sums for personnel years) for fees for patient representatives, equipment and consumables, and for outsourcing technical parts of the project. This budget for extra expenses must not exceed up to 20 percent of the total requested budget. The extra budget for outsourcing (as part of the budget for extra expenses) must not exceed 10 percent of the total requested budget. The total maximum budget for an Consortium Grant remains € 1.500.000.*

**Institute 1**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| fte | year 1 | year 2 | year 3 | year 4 | year 5 | work package(s) | total fte | budget (€) |
| Non Scientific Personnel |  |  |  |  |  |  |  |  |
| PhD |  |  |  |  |  |  |  |  |
| Junior postdoc |  |  |  |  |  |  |  |  |
| Senior postdoc |  |  |  |  |  |  |  |  |
| Materials, consumables  |  |  |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |  |  |

**Institute 2**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| fte | year 1 | year 2 | year 3 | year 4 | year 5 | work package(s) | total fte | budget (€) |
| Non Scientific Personnel |  |  |  |  |  |  |  |  |
| PhD |  |  |  |  |  |  |  |  |
| Junior postdoc |  |  |  |  |  |  |  |  |
| Senior postdoc |  |  |  |  |  |  |  |  |
| Materials, consumables |  |  |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |  |  |

**Institute X**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| fte | year 1 | year 2 | year 3 | year 4 | year 5 | work package(s) | total fte | budget (€) |
| Non Scientific Personnel |  |  |  |  |  |  |  |  |
| PhD |  |  |  |  |  |  |  |  |
| Junior postdoc |  |  |  |  |  |  |  |  |
| Senior postdoc |  |  |  |  |  |  |  |  |
| Materials, consumables |  |  |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |  |  |

**Consortium Grant Total**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| fte | year 1 | year 2 | year 3 | year 4 | year 5 | total fte | budget (€) |
| Non Scientific Personnel |  |  |  |  |  |  |  |
| PhD |  |  |  |  |  |  |  |
| Junior postdoc |  |  |  |  |  |  |  |
| Senior postdoc |  |  |  |  |  |  |  |
| Materials, consumables |  |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |  |

**2. Motivation for Personnel and Extra Expenses (max. 200 words)**

***Number of words used:***

*Give a short description of and motivation for the proposed personnel, consumables and equipment. If applicable, specify the extra budget for fees for patient representatives, equipment and consumables, and for outsourcing technical parts of the project.*

**3. Additional Funding from other Sources (if applicable, max. 100 words)**

***Number of words used:***

*Provide information on (possible) contributions by third parties.*

**4. Possible Conflicts of Interest (max. 100 words)**

***Number of words used:***

IV. SIGNATURES

**Applicant, Principal Investigator**

|  |  |
| --- | --- |
| Name | Signature |
|  |  |

**Research Team Leader 1**

|  |  |
| --- | --- |
| Name | Signature |
|  |  |

**Research Team Leader 2**

|  |  |
| --- | --- |
| Name | Signature |
|  |  |

**Research Team Leader X**

|  |  |
| --- | --- |
| Name | Signature |
|  |  |

**Autorisation Participating Institute 1** (e.g. Head of Department, Head of Institute, Director)

|  |  |
| --- | --- |
| Name |  |
|  |  |

**Autorisation Participating Institute 2** (e.g. Head of Department, Head of Institute, Director)

|  |  |
| --- | --- |
| Name | Signature |
|  |  |

**Authorisation Participating Institute X** (e.g. Head of Department, Head of Institute, Director)

|  |  |
| --- | --- |
| Name | Signature |
|  |  |